TY - JOUR
T1 - Cell therapy for central nervous system disorders
T2 - Current obstacles to progress
AU - Yasuhara, Takao
AU - Kawauchi, Satoshi
AU - Kin, Kyohei
AU - Morimoto, Jun
AU - Kameda, Masahiro
AU - Sasaki, Tatsuya
AU - Bonsack, Brooke
AU - Kingsbury, Chase
AU - Tajiri, Naoki
AU - Borlongan, Cesario V.
AU - Date, Isao
N1 - Funding Information:
This work was supported in part by Grants‐in‐Aid for Scientific Research and the Grant of the project for realization of regenerative medicine from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
Publisher Copyright:
© 2019 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue-derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor-secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.
AB - Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue-derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor-secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.
KW - Parkinson's disease
KW - cell therapy
KW - iPS cells
KW - stroke
KW - traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=85074355038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074355038&partnerID=8YFLogxK
U2 - 10.1111/cns.13247
DO - 10.1111/cns.13247
M3 - Review article
C2 - 31622035
AN - SCOPUS:85074355038
SN - 1755-5930
VL - 26
SP - 595
EP - 602
JO - CNS Neuroscience and Therapeutics
JF - CNS Neuroscience and Therapeutics
IS - 6
ER -
